


your patients




DC Bead® Bibliography

 Chemoembolization of hepatocellular carcinoma with drug eluting beads: Efficacy and doxorubicin pharmacokinetics. Varela, M., Real, M.I., Burrel, M. et al <i>Journal of Hepatology</i> 46 (2007) 474-481	 Intraarterial Hepatic Chemoembolization of Liver Metastases from Colorectal Cancer Adopting Irinotecan-Eluting Beads: Results of a Phase II Clinical Study. Fiorentini, G., Alberti, C., Turrisi, G. et al <i>In vivo</i> 21: 1085-1092 (2007)	 Preservation of the active lactone form of irinotecan using drug eluting beads for the treatment of colorectal cancer metastases. Tang, Y., Czuczman, P.R., Chung, S.T. et al <i>Journal of Controlled Release</i> 127 (2008) 70-78	 Chemoembolization of rat colorectal liver metastases with drug eluting beads loaded with irinotecan or doxorubicin. Eyo, E., Boleij, A., Taylor, R. et al <i>Clinical and Experimental Metastasis</i> (2008) 25: 273-282
 Doxorubicin eluting beads - 1: Effects of drug loading on bead characteristics and drug distribution. Lewis, A.L., Gonzalez, M.V., Leppard, S.W. et al <i>Journal of Materials Science. Special Section: Polymer Fibers</i> 2006	 Doxorubicin eluting beads - 2: Methods for evaluating drug elution and in-vitro in-vivo correlation. Gonzalez, M.V., Tang, Y., Phillips, J. et al <i>Journal of Materials Science. Special Section: Polymer Fibers</i> 2006	 Transarterial Chemoembolization of Unresectable Hepatocellular Carcinoma with Drug Eluting Beads: Results of an Open-Label Study of 62 Patients. Malagari, K., Chatzimechael, K., Alexopoulos, E. et al <i>Cardiovascular Intervent Radiol</i> (2008) 31: 289-290	 Transarterial Chemoembolization of Liver Metastases from Well Differentiated Gastroenteropancreatic Endocrine Tumors with Doxorubicin-Eluting Beads: Preliminary Results. de Baere, T., Deschamps, F., Terribile, C. et al <i>J Vasc Interv Radiol</i> 2008. 19:855-861
 Transcatheter chemoembolization in the treatment of HCC in patients not eligible for curative treatments: mid-term results of doxorubicin-loaded DC Bead. Malagari, K., Alexopoulos, E., Chatzimechael, K. et al <i>Abdominal Imaging</i> 2008; 33(5):512-9.	 Drug-Loaded Microspheres for the Treatment of Liver Cancer: Review of Current Results. Kettenbach, J., Stadler, A., van Katzel, I. et al (J. Lammer) <i>Cardiovascular Intervent Radiol</i> (2008) 31: 468-476	 Chemoembolization (TACE) of Unresectable Intrahepatic Cholangiocarcinoma with Slow-Release Doxorubicin-Eluting Beads: Preliminary Results. Alberti, C., Borea, G., Tili, M. et al <i>Cardiovascular Intervent Radiol</i> (2008)	 Doxorubicin-eluting bead-enhanced radiofrequency ablation of hepatocellular carcinoma: A pilot clinical study. Lencioni, R., Crocetti, L., Petrucci, P. et al <i>Journal of Hepatology</i> 49 (2008) 217-222

- References
- 1 Oral Presentation Prof. J. Lammer CIRSE 2008 Copenhagen 15th Sept.
 - 2 PRECISION V CRO Final Study Report.
 - 3 Sorafenib summary of product characteristics section 4.5 Bayer Healthcare Ltd.
 - 4 Varela, M., Real, M.I., Burrel, M. et al *Journal of Hepatology* 46 (2007) 474-481.
 - 5 *Prof R Lencioni Oral Presentation ASCO GI 2009, San Francisco.

DC Bead® Ordering Information			
Label Colour	Nominal Bead Size	Volume of Beads	Product Code
Yellow	100 - 300 µm	2ml	DC2V103
Blue	300 - 500 µm	2ml	DC2V305
Red	500 - 700 µm	2ml	DC2V507

Biocompatibles UK Limited
 Chapman House
 Farnham Business Park
 Weydon Lane
 Farnham, Surrey, GU9 8QL, UK
 Tel: +44 (0)1252 732 732
 Fax: +44 (0)1252 732 777
 email: marketing@biocompatibles.com
 www.biocompatibles.com



Reduce Cardiac Risk

Protect Healthy Liver

Minimise Alopecia



Protecting your patients

Minimise the toxicity of TACE, for your patients and you



Protecting

your patients




More doxorubicin, less adverse events

In the PRECISION V clinical trial, patients who received PRECISION TACE with DC Bead® had a highly significant ($p < 0.001$) reduction in doxorubicin-related serious adverse events, despite receiving 30% more doxorubicin.¹

Reduce cardiac risk

Patients receiving DC Bead were observed to have maintained or improved their cardiac function during the PRECISION V clinical trial, compared to those receiving conventional chemoembolisation.² Further clinical trials would need to be performed to establish the significance of this.



DC Bead® Combination Therapy

Kinase inhibitors are becoming increasingly evaluated in combination with chemoembolisation. Caution has been advised for patients receiving concomitant treatment with sorafenib and doxorubicin as this results in a 21% increase in patients' total systemic doxorubicin exposure (AUC).³ The favourable pharmacokinetic profile of DC Bead minimises systemic doxorubicin exposure,⁴ and suggests that DC Bead can play an important role in patients receiving combination therapy.



Improved response, no compromise in safety

"I know I would not be here today feeling so well if I had not undergone the treatment... apart from a bit of pain I recovered remarkably quickly... it has changed my life. I am 86 this year and feel very well!"

Mrs DS (Devon, UK), was first treated with DC Bead 4 years ago in 2005 for multifocal HCC.

DC Bead with its superior pharmacokinetic profile can show a significant improvement in response ($p < 0.05$) in more advanced and fragile patients without a compromise in safety. Until now these patients have not been considered as candidates for chemoembolisation (ref AASLD guideline).

More advanced patients receiving DC Bead were given a mean dose of 120mg, 33% more than the control arm yet demonstrated no deterioration in safety and a significant advantage in response ($p < 0.05$).


Protect healthy liver

The ability to preserve healthy liver in HCC patients is an important consideration when planning treatment. Patients receiving DC Bead showed significantly less elevation of liver enzymes released from healthy hepatocytes after each treatments during the PRECISION V trial, compared to conventional chemoembolisation.⁵

Further evidence of DC Beads' improved tolerability suggesting reduced risk of hepatic decompensation and an ability of patients to tolerate more DC Bead treatments.




Total Systemic Exposure - (AUC): PRECISION TACE vs Conventional TACE




↑ DC Bead® was shown by Varela et al⁴ to deliver a more targeted release of doxorubicin to the tumour, with greater consistency. Patients experienced a substantial reduction in both peak concentration and total systemic exposure to doxorubicin.

Response and Adverse Events - Advance Disease: PRECISION TACE vs Conventional TACE

Objective Response ($p = 0.038$) and Disease Control ($p = 0.026$)




Liver Enzyme Levels (AST): DC Bead vs Conventional TACE



↑ The elevation of liver enzyme levels after each of the three treatments was significantly less ($p < 0.001$) in patients receiving DC Bead®, demonstrating that PRECISION TACE with DC Bead is less toxic to healthy liver.

Liver Enzyme Levels (ALT): DC Bead vs Conventional TACE



↑ The elevation of liver enzyme levels after each of the three treatments was significantly less ($p < 0.0001$) in patients receiving DC Bead®, demonstrating that PRECISION TACE with DC Bead is less toxic to healthy liver.

- 1: T1 Pre emb 2: T1 Pre discharge 3: 1 month
- 4: T2 Pre emb 5: T2 Pre discharge 6: 3 month
- 7: T3 Pre emb 8: T3 Pre discharge 9: 6 months

